Schott Pharma AG KGaASHTPY -42.88%64 PB Ratio is 2.42 as of Jul. 02, 2026, which is 48% below its 10-year median of 4.66. GuruFocus rates SHTPY with a GF Score™ of 64/100 and a GF Value™ of $7.02. The stock has 2 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 60.86% on this metric.
The historical rank and industry rank for Schott Pharma AG KGaA's PB Ratio or its related term are showing as below:
SHTPY'
s PB Ratio Range Over the Past 10 Years
Min: 2.1 Med: 4.66 Max: 8.46
Current: 2.77
During the past 6 years, Schott Pharma AG KGaA's highest PB Ratio was 8.46. The lowest was 2.10. And the median was 4.66.
SHTPY's PB Ratio is ranked worse than 60.86% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.08
vs SHTPY: 2.77
During the past 12 months, Schott Pharma AG KGaA's average Book Value Per Share Growth Rate was 12.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 8.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 22.40% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Schott Pharma AG KGaA was 30.00% per year. The lowest was 8.00% per year. And the median was 23.50% per year.
Back to Basics: PB Ratio
Schott Pharma AG KGaA (OTCPK:SHTPY) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's PB Ratio distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Schott Pharma AG KGaA (SHTPY) has a PB Ratio of 2.42 as of Jul. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Schott Pharma AG KGaA and its competitors. This is 48% below median its historical median of 4.66. Over the past decade, Schott Pharma AG KGaA's PB Ratio has ranged from 2.10 to 8.46. According to the industry distribution chart, Schott Pharma AG KGaA ranks #479 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 60.9%.
Is Schott Pharma AG KGaA's PB Ratio too high?
Schott Pharma AG KGaA's current PB Ratio of 2.42 is 48% below median its 10-year median of 4.66. Over the past 10 years, this metric has ranged from a low of 2.10 to a high of 8.46. The Medical Devices & Instruments industry median PB Ratio is 2.08. Schott Pharma AG KGaA's value of 2.42 is 16.3% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #479 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's PB Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #479 out of 787 companies for PB Ratio. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median PB Ratio is 2.08. Schott Pharma AG KGaA's value of 2.42 is 16.3% above this benchmark. Historically, Schott Pharma AG KGaA's own PB Ratio has ranged from 2.10 to 8.46 over the past decade. While the company's 10-year median is 4.66 vs. the industry median of 2.08, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.08, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current PB Ratio of 2.42 is 16.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current PB Ratio is 2.42, which is 48% below median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (SHTPY) has a current PB Ratio of 2.42. The stock's GF Value™ is $7.02, compared to a current price of $4.37 — trading 37.7% below its estimated fair value. The current PB Ratio is 2.42, which is 48% below median its 10-year median of 4.66 and 16.3% above the Medical Devices & Instruments industry median of 2.08. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Schott Pharma AG KGaA (SHTPY), the current PB Ratio is 2.42 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (SHTPY) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of $4.37 is trading 37.7% below its estimated GF Value™ of $7.02.
Key valuation signals for SHTPY:
PB Ratio: 2.42 (48% below median its 10-year median of 4.66)
GF Value™: $7.02 vs. price of $4.37 (37.7% below fair value)
Industry Position: 16.3% above the Medical Devices & Instruments median (#479 of 787)
No single metric tells the full story. See the SHTPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score
Get the complete analysis for SHTPY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTPY has been successfully added to your 
